-
1
-
-
84878644052
-
-
7 December 2011, date last accessed
-
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. 2010. http://globocan.iarc.fr (7 December 2011, date last accessed).
-
(2010)
GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base
, vol.10
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
2
-
-
42649145828
-
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
-
Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:19-205.
-
(2008)
Cancer Treat Rev
, vol.34
, pp. 19-205
-
-
Gupta, K.1
Miller, J.D.2
Li, J.Z.3
Russell, M.W.4
Charbonneau, C.5
-
3
-
-
0036251451
-
Global increases in kidney cancer incidence, 1973-1992
-
Mathew A, Devesa SS, Fraumeni JF, Jr, Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002;11:171-8.
-
(2002)
Eur J Cancer Prev
, vol.11
, pp. 171-178
-
-
Mathew, A.1
Devesa, S.S.2
Fraumeni, J.F.3
Jr Chow, W.H.4
-
4
-
-
84873928427
-
-
based on November 2010 SEER data submission. Bethesda, MD: National Cancer Institute (NCI),16 May 2012, date last accessed
-
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (CSR), 1975-2009, National Cancer Institute (based on November 2010 SEER data submission). Bethesda, MD: National Cancer Institute (NCI) 2010. http://seer.cancer.gov/csr/1975_2009_pops09 (16 May 2012, date last accessed).
-
(2010)
SEER Cancer Statistics Review (CSR), 1975-2009, National Cancer Institute
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
-
5
-
-
84878636874
-
-
American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society,(7 December 2011, date last accessed).
-
American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771. pdf (7 December 2011, date last accessed).
-
(2011)
-
-
-
6
-
-
77955493600
-
EAU guidelines on renal cell carcinoma: the 2010 update
-
Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406.
-
(2010)
Eur Urol
, vol.58
, pp. 398-406
-
-
Ljungberg, B.1
Cowan, N.C.2
Hanbury, D.C.3
-
7
-
-
69749124027
-
Guideline for management of the clinical T1 renal mass
-
Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009;182:1271-9.
-
(2009)
J Urol
, vol.182
, pp. 1271-1279
-
-
Campbell, S.C.1
Novick, A.C.2
Belldegrun, A.3
-
9
-
-
80755140681
-
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
-
Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 2011;47:2592-602.
-
(2011)
Eur J Cancer
, vol.47
, pp. 2592-2602
-
-
Tomita, Y.1
Uemura, H.2
Fujimoto, H.3
-
10
-
-
18944385751
-
Immunotherapy for advanced renal cell cancer
-
Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425.
-
(2005)
Cochrane Database Syst Rev
, vol.1
-
-
Coppin, C.1
Porzsolt, F.2
Awa, A.3
Kumpf, J.4
Coldman, A.5
Wilt, T.6
-
11
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
12
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
13
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
-
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
14
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
-
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
-
15
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
-
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
-
16
-
-
77956048116
-
Treatment outcomes of sorafenib for first line or cytokine refractory advanced renal cell carcinoma in Japanese patients
-
Ueda T, Imamura Y, Komaru A, et al. Treatment outcomes of sorafenib for first line or cytokine refractory advanced renal cell carcinoma in Japanese patients. Int J Urol 2010;17:811-5.
-
(2010)
Int J Urol
, vol.17
, pp. 811-815
-
-
Ueda, T.1
Imamura, Y.2
Komaru, A.3
-
17
-
-
84856149515
-
Efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma
-
Suyama T, Ueda T, Fukasawa S, et al. Efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma. J Cancer Ther 2011;2:335-41.
-
(2011)
J Cancer Ther
, vol.2
, pp. 335-341
-
-
Suyama, T.1
Ueda, T.2
Fukasawa, S.3
-
18
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
19
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
-
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
20
-
-
58149337448
-
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
-
Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14: 7272-83.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7272-7283
-
-
Hu-Lowe, D.D.1
Zou, H.Y.2
Grazzini, M.L.3
-
21
-
-
44649151405
-
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors
-
Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008;9: 658-71.
-
(2008)
Curr Opin Investig Drugs
, vol.9
, pp. 658-671
-
-
Choueiri, T.K.1
-
22
-
-
72449131348
-
Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
-
Kelly RJ, Rixe O. Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 2009;4: 297-305.
-
(2009)
Target Oncol
, vol.4
, pp. 297-305
-
-
Kelly, R.J.1
Rixe, O.2
-
23
-
-
77958043734
-
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
-
Goldstein R, Pickering L, Larkin J. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert Rev Anticancer Ther 2010;10:1545-57.
-
(2010)
Expert Rev Anticancer Ther
, vol.10
, pp. 1545-1557
-
-
Goldstein, R.1
Pickering, L.2
Larkin, J.3
-
24
-
-
79959482485
-
Axitinib for the management of metastatic renal cell carcinoma
-
Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011;11:113-26.
-
(2011)
Drugs R D
, vol.11
, pp. 113-126
-
-
Escudier, B.1
Gore, M.2
-
25
-
-
35448934762
-
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
-
Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84.
-
(2007)
Lancet Oncol
, vol.8
, pp. 975-984
-
-
Rixe, O.1
Bukowski, R.M.2
Michaelson, M.D.3
-
26
-
-
50649095801
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
-
Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4708-4713
-
-
Cohen, E.E.1
Rosen, L.S.2
Vokes, E.E.3
-
27
-
-
70349388719
-
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
-
Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4462-4468
-
-
Rini, B.I.1
Wilding, G.2
Hudes, G.3
-
28
-
-
68949127256
-
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study
-
Schiller JH, Larson T, Ou SH, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-41.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3836-3841
-
-
Schiller, J.H.1
Larson, T.2
Ou, S.H.3
-
29
-
-
82555173114
-
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma
-
Fruehauf JP, Lutzky J, McDermott DF, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011;17:7462-9.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7462-7469
-
-
Fruehauf, J.P.1
Lutzky, J.2
McDermott, D.F.3
-
30
-
-
3142778420
-
Epidemiology of renal cell carcinoma
-
Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg 2004;93:88-96.
-
(2004)
Scand J Surg
, vol.93
, pp. 88-96
-
-
Lindblad, P.1
-
31
-
-
41749124973
-
Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival
-
Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008;179:1704-8.
-
(2008)
J Urol
, vol.179
, pp. 1704-1708
-
-
Stafford, H.S.1
Saltzstein, S.L.2
Shimasaki, S.3
Sanders, C.4
Downs, T.M.5
Sadler, G.R.6
-
32
-
-
34250867924
-
Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002
-
Marumo K, Kanayama H, Miyao N, et al. Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol 2007;14:479-82.
-
(2007)
Int J Urol
, vol.14
, pp. 479-482
-
-
Marumo, K.1
Kanayama, H.2
Miyao, N.3
-
34
-
-
77957272015
-
Kidney Cancer Working Group report
-
Naito S, Tomita Y, Rha SY, et al. Kidney Cancer Working Group report. Jpn J Clin Oncol 2010;40(Suppl. 1):i51-6.
-
(2010)
Jpn J Clin Oncol
, vol.40
, Issue.SUPPL. 1
-
-
Naito, S.1
Tomita, Y.2
Rha, S.Y.3
-
35
-
-
84865473303
-
Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study
-
May 20,abstr 4503
-
Rini BI, Grünwald V, Fishman MN, et al. Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 2012;30, No. 15 (May 20 Suppl; abstr 4503).
-
(2012)
J Clin Oncol
, vol.30
, Issue.15 SUPPL.
-
-
Rini, B.I.1
Grünwald, V.2
Fishman, M.N.3
-
36
-
-
84878668259
-
-
Nexavarw (sorafenib) prescribing information.New Jersey Bayer Healthcare Pharmaceuticals Inc, 27 June 2012, date last accessed
-
Nexavarw (sorafenib) prescribing information. New Jersey Bayer Healthcare Pharmaceuticals Inc 2005 http://labeling.bayerhealthcare. com/html/products/pi/Nexavar_PI.pdf (27 June 2012, date last accessed).
-
(2005)
-
-
-
37
-
-
33745141600
-
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
-
Cella D, Yount S, Du H, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 2006;4:191-9.
-
(2006)
J Support Oncol
, vol.4
, pp. 191-199
-
-
Cella, D.1
Yount, S.2
Du, H.3
-
38
-
-
34447569323
-
Development and validation of a scale to measure disease-related symptoms of kidney cancer
-
Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007;10:285-93.
-
(2007)
Value Health
, vol.10
, pp. 285-293
-
-
Cella, D.1
Yount, S.2
Brucker, P.S.3
-
39
-
-
8944243553
-
Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system
-
Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 1996;5:309-20.
-
(1996)
Qual Life Res
, vol.5
, pp. 309-320
-
-
Bonomi, A.E.1
Cella, D.F.2
Hahn, E.A.3
-
40
-
-
18244368960
-
A comprehensive method for the translation and cross-cultural validation of health status questionnaires
-
Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 2005;28:212-32.
-
(2005)
Eval Health Prof
, vol.28
, pp. 212-232
-
-
Eremenco, S.L.1
Cella, D.2
Arnold, B.J.3
-
41
-
-
17144423549
-
Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation
-
Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8:94-104.
-
(2005)
Value Health
, vol.8
, pp. 94-104
-
-
Wild, D.1
Grove, A.2
Martin, M.3
-
42
-
-
84878640468
-
-
New York, NY: Pfizer Inc 2012,30 August 2012, date last accessed
-
Inlytaw (axitinib) tablets prescribing information. New York, NY: Pfizer Inc 2012. http://labeling.pfizer.com/ShowLabeling.aspx?id=759 (30 August 2012, date last accessed).
-
Inlytaw (axitinib) tablets prescribing information.
-
-
-
43
-
-
77956227464
-
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
-
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65.
-
(2010)
Cancer
, vol.116
, pp. 4256-4265
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
44
-
-
72149129759
-
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients
-
Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317-25.
-
(2010)
Eur Urol
, vol.57
, pp. 317-325
-
-
Naito, S.1
Yamamoto, N.2
Takayama, T.3
-
45
-
-
36249017922
-
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
-
Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62.
-
(2007)
Jpn J Clin Oncol
, vol.37
, pp. 755-762
-
-
Akaza, H.1
Tsukamoto, T.2
Murai, M.3
Nakajima, K.4
Naito, S.5
-
46
-
-
84879321714
-
Axitinib vs Sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors
-
abstr 793PD
-
Motzer RJ, Escudier B, Tomczak P, et al. Axitinib vs Sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors. Ann Oncol 2012;23:ix262. (Suppl 9; abstr 793PD).
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL. 9
-
-
Motzer, R.J.1
Escudier, B.2
Tomczak, P.3
-
47
-
-
75549086120
-
Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
-
Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010;65:563-70.
-
(2010)
Cancer Chemother Pharmacol
, vol.65
, pp. 563-570
-
-
Pithavala, Y.K.1
Tortorici, M.2
Toh, M.3
-
48
-
-
77957269382
-
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients
-
Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 2010;101:963-8.
-
(2010)
Cancer Sci
, vol.101
, pp. 963-968
-
-
Mukohara, T.1
Nakajima, H.2
Mukai, H.3
-
49
-
-
84864351085
-
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
-
Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs 2012;30:1055-64.
-
(2012)
Invest New Drugs
, vol.30
, pp. 1055-1064
-
-
Fujiwara, Y.1
Kiyota, N.2
Chayahara, N.3
-
50
-
-
84864287868
-
Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
-
Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 2012;68:645-55.
-
(2012)
Eur J Clin Pharmacol
, vol.68
, pp. 645-655
-
-
Brennan, M.1
Williams, J.A.2
Chen, Y.3
Tortorici, M.4
Pithavala, Y.5
Liu, Y.C.6
-
51
-
-
84856512778
-
A population pharmacokinetic (PK) analysis to evaluate the potential effect of the UGT1A1*28 genotype on the PK of AG-013736, an anti-angiogenic agent
-
abstr PI-28
-
Garrett M, Houk BE, Myrand SP, Hee B, Mota J, Pithavala YK. A population pharmacokinetic (PK) analysis to evaluate the potential effect of the UGT1A1*28 genotype on the PK of AG-013736, an anti-angiogenic agent. Clin Pharmacol Ther 2007;81:S21 (Suppl 1; abstr PI-28).
-
(2007)
Clin Pharmacol Ther
, vol.81
, Issue.SUPPL. 1
-
-
Garrett, M.1
Houk, B.E.2
Myrand, S.P.3
Hee, B.4
Mota, J.5
Pithavala, Y.K.6
|